<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171457</url>
  </required_header>
  <id_info>
    <org_study_id>CHTF919DUS45</org_study_id>
    <nct_id>NCT00171457</nct_id>
  </id_info>
  <brief_title>The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.</brief_title>
  <official_title>The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Investigate the role of tegaserod in modulating gastric sensitivity to mechanical distention
      of the stomach
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if tegaserod 6 mg b.i.d modulates gastric sensitivity to mechanical distention of the stomach</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) Comparing effects at end of treatment compared to baseline:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To verify that tegaserod modulates esophageal sensitivity to esophageal distention</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if tegaserod improves individual dyspeptic symptoms of epigastric pain/discomfort</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if tegaserod improves heartburn and/or regurgitation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if tegaserod is preferred by patients with functional heartburn &amp; accompanying dyspepsia &amp; gastric mechanical sensitivity over placebo</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine if there is a correlation between esophageal &amp; gastric mechanosensitivity thresholds in this patient group, and to determine if tegaserod alters this relationshi</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Heartburn</condition>
  <condition>Dyspepsia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegaserod</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects at least 18 years of age.

          -  Subjects willing to undergo multiple nasogastric intubations.

          -  Patients with functional heartburn will need to meet ROME II criteria.

          -  Patients with symptoms consistent with dyspepsia (epigastric pain/discomfort
             characterized by bloating, postprandial fullness and early satiety)

        Exclusion Criteria:

          -  Subjects with clinically significant diarrhea or a diagnosis of diarrhea-predominant
             IBS.

          -  Subjects with a diagnosis of IBD, Barrett's esophagus, esophageal stricture or ring,
             or previous or current history of ulcer disease.

          -  Subjects with Diffuse Esophageal Spasm or Achalasia.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma Foundation for Digestive Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>October 9, 2007</last_update_submitted>
  <last_update_submitted_qc>October 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2007</last_update_posted>
  <keyword>functional heartburn</keyword>
  <keyword>dyspepsia</keyword>
  <keyword>male</keyword>
  <keyword>female</keyword>
  <keyword>visceral sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegaserod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

